Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 187-196 , February 2008

HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR

  • Richard F. Schlenk

      Affiliations

    • University of Ulm, Ulm, Germany
    • ,
  • Marcelo C. Pasquini

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • Corresponding Author InformationCorrespondence and reprint requests: Marcelo C. Pasquini, MD, MS, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 8701 Watertown Plank Road, P.O. Box 26509, Milwaukee, Wisconsin, 53226.
    • ,
  • Waleska S. Pérez

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Jürgen Krauter

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • ,
  • Joseph H. Antin

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Asad Bashey

      Affiliations

    • BMT Group of Georgia, Atlanta, Georgia
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Thomas Büchner

      Affiliations

    • University of Munster, Munster, Germany
    • ,
  • Jean-Yves Cahn

      Affiliations

    • Chu-Grenoble, Grenoble, France
    • ,
  • Mitchell S. Cairo

      Affiliations

    • Columbia University Medical Center, New York, New York
    • ,
  • Edward A. Copelan

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Corey S. Cutler

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts
    • ,
  • Hartmut Döhner

      Affiliations

    • University of Ulm, Ulm, Germany
    • ,
  • Robert Peter Gale

      Affiliations

    • Center for the Advanced Studies in Leukemia, Los Angeles, California
    • ,
  • Osman Ilhan

      Affiliations

    • Ibni Sinai Hospital, Ankara, Turkey
    • ,
  • Hillard M. Lazarus

      Affiliations

    • University Hospitals of Cleveland, Cleveland, Ohio
    • ,
  • Jane L. Liesveld

      Affiliations

    • University of Rochester Medical Center, Rochester, New York
    • ,
  • Mark R. Litzow

      Affiliations

    • Mayo Clinic, Rochester, Minnesota
    • ,
  • David I. Marks

      Affiliations

    • Bristol Children's Hospital, Bristol, United Kingdom
    • ,
  • Richard T. Maziarz

      Affiliations

    • Oregon Health Sciences University, Portland, Oregon
    • ,
  • Philip L. McCarthy

      Affiliations

    • Roswell Park Cancer Institute, Buffalo, New York
    • ,
  • Stephen D. Nimer

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Jorge Sierra

      Affiliations

    • Hospital de Sant Pau, Barcelona, Spain
    • ,
  • Martin S. Tallman

      Affiliations

    • Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Daniel J. Weisdorf

      Affiliations

    • University of Minnesota, Minneapolis, Minnesota
    • ,
  • Mary M. Horowitz

      Affiliations

    • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Arnold Ganser

      Affiliations

    • Hannover Medical School, Hannover, Germany
    • ,
  • CIBMTR Acute Leukemia Working Committee

Received 14 June 2007 ,Accepted 22 October 2007.

References 

  1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms 10.1182/blood-2002-04-1199. Blood. 2002;100:2292–2302
  2. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135:165–173
  3. Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–5717
  4. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741–3750
  5. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992;80:1825–1831
  6. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083
  7. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462–469
  8. Schlenk RF, Benner A, Hartmann F, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521–1528
  9. Billstrom R, Johansson B, Fioretos T, et al. Poor survival in t(8;21) (q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol. 1997;59:47–52
  10. O'Brien S, Kantarjian HM, Keating M, et al. Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21. J Clin Oncol. 1989;7:1081–1086
  11. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517–3523
  12. Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22). Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77
  13. Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288–1295
  14. Heil G, Krauter J, Raghavachar A, et al. Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial. Ann Hematol. 2004;83:336–344
  15. Schaich M, Ritter M, Illmer T, et al. Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia. Br J Haematol. 2001;112:300–307
  16. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and 1 course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21:4496–4504
  17. Büchner T, Hiddemann W, Berdel WE, et al. Upfront randomized TAD-HAM vs HAM-HAM induction, G-CSF priming vs no G-CSF, and prolonged maintenance vs autologous transplantation in de novo AML, secondary AML and high-risk MDS and Their Subgroups according to cytogenetics and LDH: interim analysis. Blood. 2002;100:345a
  18. Mitelman F. ISCN: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Krager; 1995;
  19. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642–4649
  20. Klein J, Moeschberger ML. Survival Analysis: Techniques of censored and truncated data. New York: Springer-Verlag; 2003;
  21. Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187–200
  22. Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359:1309–1310
  23. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1997;90:2978–2986
  24. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–1656
  25. Gale RP, Buchner T, Zhang MJ, et al. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia. 1996;10:1687–1691
  26. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–223
  27. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385–400
  28. Pasquini M. Current use and outcome of hematopoietic stem cell transplantation: part I— CIBMTR Summary Slides, 2005. CIBMTR Newslett. [serial online]. 2005;12:5–8
  29. Stem Cell Trialists' Collaborative G. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–5087
  30. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181
  31. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525–1531
  32. Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 2002;100:761–767
  33. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333
  34. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102:1104–1109
  35. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24:3904–3911
  36. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791–1799
  37. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–3775

 The first two authors contributed equally to this article.

PII: S1083-8791(07)00528-9

doi: 10.1016/j.bbmt.2007.10.006

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 187-196 , February 2008

Article Tools

* Image Usage & Resolution